Inflammatory Bowel Disease Market Forecast (2022-2027)
Inflammatory Bowel Disease Market Size is estimated to reach $26.3 billion by 2027 and is poised to grow at a CAGR of 5.9% over the forecast period of 2022-2027. Inflammatory bowel disease (IBD) is an umbrella term used to describe disorders that involve chronic inflammation of the digestive tract. It includes ulcerative colitis, a condition in which inflammation and soreness of the superficial lining of the rectum and colon, and in Crohns disease affect any part of the gastrointestinal tract. The cause of IBD is unknown, but it mostly occurred after weaken immunity power. Some agent or combination of agents such as bacteria, viruses, and antigens are considered as responsible to trigger the immune system, and causing inflammation. The common symptoms of IBD are abdominal pain, weight loss, persistent diarrhea, rectal bleeding, and fatigue. To treat such disease medication with amino-salicylates, immunomodulators, antibiotics, corticosteroids, and biologics are used. According to a Medscape article published in 2020, the highest rate of IBD is assumed to be in developed countries. The incidence of IBD is between 0.5-24.5 cases per 100,000 person-years for Crohns disease and 0.1-16 cases per 100,000 person-years for ulcerative colitis globally.
Such growing occurrence of Crohns disease and ulcerative colitis in developed countries, and growing consciousness across the world propel the growth of the Inflammatory Bowel Disease Industry. Also, the presence of key market players and rising research and developments support the growth of the Inflammatory Bowel Disease Market Size. For instance, in May 2022, Food and Drug Organization approved the new drug Zeposia for treating moderate to severe ulcerative colitis in adults. Such new products launched in the market, and expansion in key market players further fuel the growth of the Inflammatory Bowel Disease Industry over the forecast period 2022-2027.
Inquiry Before Buying
Inflammatory Bowel Disease Market Report Coverage
The report: “Inflammatory Bowel Disease Market Forecast (2022-2027)", by Industry ARC covers an in-depth analysis of the following segments in the Inflammatory Bowel Disease Market.
Key Takeaways
- Geographically, North America held a dominant market share in the year 2021, owing to the increasing prevalence of Inflammatory Bowel Diseases, and developed healthcare facilities assist the growth of the Inflammatory Bowel Disease Market Size in this region.
- The rising consciousness among consumers propels the growth of the Inflammatory Bowel Disease Market Size in this region.
- The Inflammatory Bowel Disease Market is predicted to grow owing to the growing burden of Inflammatory Bowel Disease around the world and raising consciousness among consumers. However, the high price of treatment may limit market growth over the forecast period 2022-2027.
- A detailed analysis of strengths, weaknesses, opportunities, and threats will be provided in the Inflammatory Bowel Disease Market Report.
Inflammatory Bowel Disease Market Segment Analysis- By Type
The Inflammatory Bowel Disease Market based on type can be further segmented into Ulcerative Colitis and Crohns Disease. The Crohn’s segment held a dominant market share in the year 2021. This is owing to the increasing prevalence of Crohns disease and growing number of patients undergoing treatment for Crohns disease around the world. The inflammatory symptoms of Crohn disease can progress from mild to moderate to severe invasive (fistulization) or stricturing disease. To treat this type of condition anti-TNF agents like infliximab, adalimumab, golimumab and others are used. Growing research and developments in healthcare sector and increasing awareness about Inflammatory Bowel Disease around the world fuel market growth. For instance, in May 2022, a tool was developed with help of artificial intelligence to predict the postoperative recurrence of Crohns disease. Such rapid growth in technology and growing investment in the healthcare sector drive the growth of the Inflammatory Bowel Disease Market Share.
However, Ulcerative Colitis is estimated to grow with the fastest CAGR rate of 6.2% over the forecast period 2022-2027. As ulcerative colitis can affect any part of the digestive tract and have a possibility to stand as a lifelong illness, hence treatment for ulcerative colitis is in demand. To early diagnose this type of disease various diagnostics methods like serologic markers, complete blood cell count, comprehensive metabolic panel, inflammation markers, and stool assay are getting demand in the market. As per Crohn’s & Colitis UK in 2022 predict, 1 in every 123 people in the UK have either Crohns disease or ulcerative colitis. This amounts to a total of nearly half a million people in the UK living with IBD. Such increasing cases of IBD related diseases, especially ulcerative colitis propels the growth of the Inflammatory Bowel Disease Market share over the forecast period 2022-2027.
Inflammatory Bowel Disease Market Segment Analysis- By Route of Administration
Inflammatory Bowel Disease Market based on the route of administration can be further segmented into Oral, and Injectables. The injectables segment held a dominant market share in the year 2021. This is the result of the increasing use of biologics for the treatment of ulcerative colitis and Crohns disease. For instance, in February 2021, AbbiVie Inc, announced the FDA approval of HUMIRA to treat moderate to severely active ulcerative colitis in pediatric patients. Such a growing number of new products like amino-salicylates, immunomodulators, antibiotics, corticosteroids, and biologics in the market and increasing demand for biologics drive the growth of the Inflammatory Bowel Disease Market shares.
However, Oral is estimated to grow with the fastest CAGR rate of 5.7% over the forecast period 2022-2027. This is owing to the growing demand for oral drugs in the treatment of inflammatory bowel disease. Also, oral drug offer a better and more convenient option to control disease progression and improve quality of life. In May 2021, Ozanimod get FDA approval for relapsing forms of multiple sclerosis, in the United States for a second high-need medical condition, ulcerative colitis. Such growing developments in the treatment of inflammatory bowel disease fuel the growth of the Inflammatory Bowel Disease Market Share over the forecast period 2022-2027.
Inflammatory Bowel Disease Market Segment Analysis- By Geography
The Inflammatory Bowel Disease Market based on Geography can be further segmented into North America, Europe, Asia-Pacific, South America, and the Rest of the World. North America held a dominant market share of 38% in the year 2021. This is the result of the increasing number of cases of inflammatory bowel disease in this region. As per Medscape in 2020, North America reported 319 cases per 100,000 people. As per Crohn’s & Colitis Foundation, about 70,000 new cases of IBD are diagnosed in the United States each year. Such a growing prevalence of IBD cases and the presence of developed healthcare facilities in this region drive the growth of the Inflammatory Bowel Disease Market Size.
Furthermore, Asia-Pacific is estimated to grow with the fastest CAGR rate of 6.5% over the forecast period 2022-2022. This is owing to the increasing awareness about inflammatory bowel disease in this region. Increasing healthcare spending and better diagnostics techniques available in the region improve the diagnosis of inflammatory bowel disease. According to the research paper published in BMC Gastroenterology in 2021, compared to 2020 cases of inflammatory bowel disease is expected to raise by 2.5 fold in Iran with 69 thousand cases, 2.3 fold increment in North Africa and the Middle East with 220 thousand cases. Also, quadrupling prevalence in India with 2.2 million cases, 1.5 fold increases in East-Asia with 4.5 million cases. Such increasing prevalence of IBD and growing demand for diagnostics fuel the growth of the Inflammatory Bowel Disease Market Size in this region over the forecast period 2022-2027.
Inflammatory Bowel Disease Market Drivers:
Increasing Rate of Inflammatory Disease Drive the Market Growth.
The increasing prevalence of inflammatory disease and growing number of patients undertaking treatment for inflammatory bowel disease drive the inflammatory bowel disease industry. Inflammatory bowel disease is tiggered with genetic predisposition, environmental triggers, and immune system disturbance. The majority of cases show family history is most prevalent cause of inflammatory bowel disease. The majority of monogenic IBD cases occur in children diagnosed under 6 years of age. Recent advanced in technology like next generation sequencing make it easier to diagnose such rear genetic disease. According to the American Gastroenterological Association (AGA) report published in 2020, the forecasted IBD prevalence in 2030 was 981 per 100,000 including 493 per 100,000 with Crohns Disease and 436 per 100,000 with Ulcerative Colitis. Such increasing cases of inflammatory bowel disease fuel the growth of the Inflammatory Bowel Disease Industry over the forecast period 2022-2027.
Strong Portfolio of Pipeline Molecules to Increase Product Launches Drives the Market Growth.
With rising prevalence of inflammatory bowel disease and increasing awareness in about such rear disease in people around the world create strong demand for early diagnosis techniques and medication are the major factors responsible for market growth. According to ClinicalTrials.gov more than 145 studies are open for treatment of Crohns disease and ulcerative colitis, and majority of the molecules are in the final phase of the clinical trials. In March 2022, Tiziana announced the initiation of phase 1b clinical trial in Crohns disease patients to evaluate oral capsules of Foralumab, a fully human Anti-CD3 monoclonal antibody. According to ClinicalTrials.gov total of 4216 participants are registered under patient registry for clinical trials of inflammatory bowel disease. Such raising clinical trials and number of molecules are in the final phase available new drugs such as amino-salicylates, immunomodulators, antibiotics, corticosteroids, and biologics for treatment of IBD. Such increasing clinical trials and approvals for new drug fuels the growth of the Inflammatory Bowel Disease Industry over the forecast period 2022-2027.
Inflammatory Bowel Disease Market Challenges:
High Treatment Cost is Hampering the Market Growth.
In developing countries, there is a lack of awareness about inflammatory bowel disease and a lack of proper diagnostic techniques which reduce the number of patients undergoing treatment. The price of drugs like amino-salicylates, immunomodulators, antibiotics, corticosteroids, and biologics are high in low and middle-income countries. Also, low income and high burden of healthcare expenditure limits access to the treatment. As per the world Bank Report published in June 2022 about ‘Global Economic Prospect’ the rising risk of stagflation with potentially harmful for middle and low-income countries. According to the World Bank the global growth is expected to slump from 5.7 percent in 2021 to 2.9 percent in 2022. As per World Health Organisation (WHO), in low and middle-income countries out-of-pocket spending was the main source of health expenditure (44%). Owing to such conditions most of people are away from good healthcare facilities and such factors may hamper market growth over the forecast period 2022-2027.
Inflammatory Bowel Disease Market Industry Outlook:
Product launches, mergers and acquisitions, joint ventures, and geographical expansions are key strategies adopted by players in the Inflammatory Bowel Disease Market. The top 10 companies in the Inflammatory Bowel Disease Market are:
- ABBOTT LABORATORIES
- Amgen Inc.
- ASTRAZENECA PLC
- ELI-LILLY
- INDEX PHARMACEUTICALS HOLDINGS AB
- GLAXOSIMITHKLINE PLC
- JOHNSON & JOHNSON
- Merck & Co. Inc.
- Pfizer Inc.
- SANOFI S.A
Recent Developments
- In April 2022, GlaxoSimithKline PLC, announced agreement to acquire Sierra Oncology, a California-based, late-stage biopharmaceutical company focused on targeted therapies for the treatment of rare forms of cancer for $ 1.9 billion.
- In March 2021, In order to gain access to a preclinical programme that has the potential to support tissue repair and regeneration, Amgen purchased the privately held Rodeo Therapeutics company. Investors in the Rodeo earned an initial payout of $55 million plus potentially to $666 million in subsequent milestone payments. The deal has previously been accepted by the board of directors and shareholders of the Seattle-based company Rodeo. The smaller company is creating treatments that work to impede an enzyme called 15-prostaglandin dehydrogenase, or 15-PGDH, which is responsible for the body's repair processes.
- In January 2020, Brazikumab, an interleukin 23 (IL-23) inhibitor currently being developed for inflammatory bowel disease (IBD), will have its global rights acquired by AstraZeneca from Allergan. Allergan and AstraZeneca will end their current license agreement, and AstraZeneca will receive full ownership of brazikumab.
- For more Lifesciences and Healthcare Market reports, please click here
Comments
Post a Comment